- Home
- Media Center
Media Center
Catch up on the latest Johnson & Johnson news and download the J&J logo and media assets here.
At Johnson & Johnson our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal.
Featured press releases
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2 In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, or reported sexual side effects1,2 In a six-month open-label extension safety study, safety profile was consistent with pivotal studies and 80% of MDD patients taking CAPLYTA® achieved response, with 65% of patients reaching remission from depression3 CAPLYTA® offers a new option for the 2 in 3 people who experience residual symptoms despite their current antidepressant treatment1,2,3
Johnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis
Expanded STELARA® indication seeks to treat children two years of age and older with moderately to severely active ulcerative colitis, based on Week 52 data from UNIFI Jr
Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook
• 2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%* • 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80 • Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump • Company increases full year estimated reported sales5 guidance to $93.7B or 5.7% at the midpoint; reaffirms full year adjusted EPS4 guidance of $10.85 at the midpoint, absorbing higher tax costs
Media assets for download
Johnson & Johnson logos
Johnson & Johnson b-roll
Johnson & Johnson photographs
Wilson, North Carolina manufacturing facility images and b-roll
All press releases
More from Johnson & Johnson
Our company
We are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow.
Policies and reports
The print and digital publications we produce each year that recap the company’s business performance and key enterprise-wide milestones.